Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicole Giocanti

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Bulletin Du Cancer|January 7, 2006
[Targeted therapies and radiotherapy]Christophe Hennequin, Nicole Giocanti, Vincent Favaudon
The Prostate|November 11, 2009
Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cellsLaurent Quéro, Nicole Giocanti, Christophe Hennequin, et al.
Targeted Oncology|December 16, 2015
Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS StatusFlorence Huguet, Marie Fernet, Nicole Giocanti, et al.
BMC Cell Biology|July 18, 2003
Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recoveryGeorges Noël, Nicole Giocanti, Marie Fernet, et al.
Molecular Cancer Therapeutics|February 19, 2008
Growth inhibition by STI571 in combination with radiation in human chronic myelogenous leukemia K562 cellsFlorence Huguet, Nicole Giocanti, Christophe Hennequin, et al.
Molecular Cancer Therapeutics|March 21, 2006
Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesisGeorges Noël, Camille Godon, Marie Fernet, et al.
International Journal of Radiation Oncology, Biology, Physics|November 16, 2010
Radiobiological characterization of two therapeutic proton beams with different initial energy spectra used at the Institut Curie Proton Therapy Center in OrsayValentin Calugaru, Catherine Nauraye, Georges Noël, et al.
Nucleic Acids Research|July 8, 2008
PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibilityCamille Godon, Fabrice P Cordelières, Denis Biard, et al.
Molecular Cancer Therapeutics|October 18, 2005
A role for PKCzeta in potentiation of the topoisomerase II activity and etoposide cytotoxicity by wortmanninCaroline Reis, Nicole Giocanti, Christophe Hennequin, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Bulletin Du Cancer|January 7, 2006
[Targeted therapies and radiotherapy]Christophe Hennequin, Nicole Giocanti, Vincent Favaudon
The Prostate|November 11, 2009
Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cellsLaurent Quéro, Nicole Giocanti, Christophe Hennequin, et al.
Targeted Oncology|December 16, 2015
Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS StatusFlorence Huguet, Marie Fernet, Nicole Giocanti, et al.
BMC Cell Biology|July 18, 2003
Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recoveryGeorges Noël, Nicole Giocanti, Marie Fernet, et al.
Molecular Cancer Therapeutics|February 19, 2008
Growth inhibition by STI571 in combination with radiation in human chronic myelogenous leukemia K562 cellsFlorence Huguet, Nicole Giocanti, Christophe Hennequin, et al.
Molecular Cancer Therapeutics|March 21, 2006
Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesisGeorges Noël, Camille Godon, Marie Fernet, et al.
International Journal of Radiation Oncology, Biology, Physics|November 16, 2010
Radiobiological characterization of two therapeutic proton beams with different initial energy spectra used at the Institut Curie Proton Therapy Center in OrsayValentin Calugaru, Catherine Nauraye, Georges Noël, et al.
Nucleic Acids Research|July 8, 2008
PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibilityCamille Godon, Fabrice P Cordelières, Denis Biard, et al.
Molecular Cancer Therapeutics|October 18, 2005
A role for PKCzeta in potentiation of the topoisomerase II activity and etoposide cytotoxicity by wortmanninCaroline Reis, Nicole Giocanti, Christophe Hennequin, et al.
Pageof 1